SERB Pharmaceuticals expands leading emergency care portfolio with acquisition of Aurlumyn™ (iloprost IV) for severe frostbite
October 21, 2024 08:00 ET
|
SERB Pharmaceuticals
Philadelphia, PA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today the acquisition of Aurlumyn™ (iloprost IV), the only FDA approved...
FDA has accepted a BLA for bentracimab, the first and only ticagrelor reversal agent, for filing and priority review
August 02, 2024 08:35 ET
|
SERB Pharmaceuticals
Pleasanton, CA and Philadelphia, PA, Aug. 02, 2024 (GLOBE NEWSWIRE) -- SFJ Pharmaceuticals, (SFJ), Sponsor of the bentracimab Biologics License Application (BLA), and SERB Pharmaceuticals (SERB),...
SERB Pharmaceuticals strengthens leadership in medical countermeasures with the global acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit for $75 million
July 31, 2024 09:06 ET
|
SERB Pharmaceuticals
Philadelphia, PA, July 31, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today the acquisition of RSDL® (Reactive Skin Decontamination Lotion)...
SERB Pharmaceuticals grants exclusive license to M8 Pharmaceuticals, an Acino company, to bring Voraxaze® (Glucarpidase) to cancer patients in Latin America
March 20, 2024 10:00 ET
|
SERB Pharmaceuticals
Paris, March 20, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company, and M8 Pharmaceuticals, an Acino company (“M8”) are collaborating to bring an...
SERB Pharmaceuticals acquires Vistogard® and Xuriden® from Wellstat Therapeutics
July 13, 2023 08:00 ET
|
SERB Pharmaceuticals
West Conshohocken, PA, July 13, 2023 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today that it has acquired two life-saving medicines, Vistogard®...
SERB Pharmaceuticals and SFJ Pharmaceuticals announce a U.S. partnership for bentracimab, a ticagrelor reversal agent
May 11, 2023 07:28 ET
|
SERB Pharmaceuticals
PHILADELPHIA and SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, and SFJ Pharmaceuticals, a global drug development company, announce...
SERB presents preclinical data showing initial efficacy of COVID-19 treatment developed with polyclonal antibody platform
October 19, 2022 08:24 ET
|
SERB Pharmaceuticals
Washington D.C., Oct. 19, 2022 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals today announces preclinical data demonstrating initial efficacy of a new polyclonal, ovine fragment antibody (Fab) developed...